deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT02851745

Effects of Linagliptin on Left Ventricular Myocardial DYsfunction in Patients With Type 2 DiAbetes Mellitus and Concentric Left Ventricular Geometry (DYDA2)

Effects of the Dipeptidyl Peptidase-4 (DPP-4) Inhibitor Linagliptin on Left Ventricular Myocardial DYsfunction in Patients With Type 2 DiAbetes Mellitus and Concentric Left Ventricular Geometry

Sponsor: Fondazione dell'Associazione Medici Diabetologi

Conditions Diabetes Mellitus, Type 2 Left Ventricular Systolic Dysfunction
Interventions Linagliptin Placebo
Updated 13 times since 2017 Last updated: May 21, 2021 Started: Jul 31, 2015 Primary completion: Jul 2, 2019 Completion: Jul 2, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02851745, this PHASE3 trial focuses on Diabetes Mellitus, Type 2 and Left Ventricular Systolic Dysfunction and remains completed. Sponsored by Fondazione dell'Associazione Medici Diabetologi, it has been updated 13 times since 2015, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Aug 2019 · 11 months · monthly snapshot~Aug 2019 – ~Sep 2020 · 13 months · monthly snapshot~Sep 2020 – ~Nov 2020 · 2 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Jun 2021 · 3 months · monthly snapshot~Jun 2021 – ~Jul 2024 · 37 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 7 months · monthly snapshot~Jan 2026 – present · 3 months · monthly snapshot

Change History

13 versions recorded

  1. Jan 2026 — Present [monthly]

    Completed PHASE3

  2. Sep 2025 — Present [monthly]

    Completed PHASE3

  3. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  5. Jun 2021 — Jul 2024 [monthly]

    Completed PHASE3

▶ Show 8 earlier versions

  1. Mar 2021 — Jun 2021 [monthly]

    Completed PHASE3

  2. Jan 2021 — Mar 2021 [monthly]

    Completed PHASE3

  3. Nov 2020 — Jan 2021 [monthly]

    Completed PHASE3

  4. Sep 2020 — Nov 2020 [monthly]

    Completed PHASE3

  5. Aug 2019 — Sep 2020 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  6. Sep 2018 — Aug 2019 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  7. Jun 2018 — Sep 2018 [monthly]

    Recruiting PHASE3

  8. Jan 2017 — Jun 2018 [monthly]

    Recruiting PHASE3

    First recorded

Jul 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Fondazione dell'Associazione Medici Diabetologi
  • Heart Care Foundation
Data source: Heart Care Foundation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bergamo, Italy , Catania, Italy , Chieri, Italy , Copertino, Italy , Cuneo, Italy , Genova, Italy , Messina, Italy , Milan, Italy , Napoli, Italy , Rapallo, Italy and 7 more locations